CoChat

Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I Disorder

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: The authors determined the efficacy and safety of asenapine in preventing recurrence of any mood episode in adults with bipolar I disorder. METHOD: Adults with an acute manic or mixed episode per DSM-IV-TR criteria were enrolled in this randomized, placebo-controlled trial consisting of an initial 12- to 16-week open-label period and a 26-week double-blind randomized withdrawal period. The target asenapine dosage was 10 mg b.i.d. in the open-label period but could be titrated down to 5 mg b.i.d. After completing the open-label period, subjects meeting stabilization/stable-responder criteria were randomized to asenapine or placebo treatment in the double-blind period. The primary efficacy endpoint was time to recurrence of any mood event during the double-blind period. Kaplan-Meier estimation was performed, and 95% confidence intervals were determined. Safety was assessed throughout. RESULTS: A total of 549 subjects entered the open-label period, of whom 253 enrolled in the double-blind randomized withdrawal period (127 in the placebo group; 126 in the asenapine group). Time to recurrence of any mood episode was statistically significantly longer for asenapine- than placebo-treated subjects. In post hoc analyses, significant differences in favor of asenapine over placebo were seen in time to recurrence of manic and depressive episodes. The most common treatment-emergent adverse events were somnolence (10.0%), akathisia (7.7%), and sedation (7.7%) in the open-label period and mania (11.9% of the placebo group compared with 4.0% of the asenapine group) and bipolar I disorder (6.3% compared with 1.6%) in the double-blind period. CONCLUSIONS: Long-term treatment with asenapine was more effective than placebo in preventing recurrence of mood events in adults with bipolar I disorder and was generally well-tolerated.

Overview

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2017.16040419

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 10 references

Cited by

See all 66

Metadata

Authors
Szegedi, A., Durgam, S., Mackle, M., Yu, S. Y., Wu, X., Mathews, M., & Landbloom, R. P.
Affiliations
From Allergan, Jersey City, N.J.; Merck, Whitehouse Station, N.J.; and Forest Research Institute, Jersey City, N.J.
Venue
American Journal of Psychiatry
Published
2018-01
Volume
175
Issue
1
Pages
71-79
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2756852815
Cited by
66
References
10
Citations by year
2026: 2 · 2025: 5 · 2024: 5 · 2023: 4 · 2022: 3 · 2021: 29 · 2020: 7 · 2019: 5 · 2018: 3
FWCI
3.84
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
asenapine, bipolar I disorder, manic episodes, mixed states, maintenance therapy, mood episode recurrence, antipsychotic efficacy, antipsychotic safety, akathisia, sleepiness
MeSH terms
Adult, Affect, Bipolar Disorder, Dibenzocycloheptenes, Dose-Response Relationship, Drug, Double-Blind Method, Female, Heterocyclic Compounds, 4 or More Rings, Humans, Male, Psychiatric Status Rating Scales, Time, Antipsychotic Agents, Treatment Outcome, Drug Monitoring, Diagnostic and Statistical Manual of Mental Disorders, Kaplan-Meier Estimate, Patient Acuity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I Disorder. https://app.cochat.ai/papers/10.1176/appi.ajp.2017.16040419
The paper
Szegedi, A., Durgam, S., Mackle, M., Yu, S. Y., Wu, X., Mathews, M., & Landbloom, R. P. (2018). Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I Disorder. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2017.16040419

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.